Poland· PL-100470747
Yselty
A linzagolix product containing linzagolixum cholini, registered in Poland by Theramex Ireland Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Linzagolix is registered in 12 of 19 countries.
Countries holding a registration under ATC H01CC04 (linzagolix), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Linzagolix · ATC H01CC04
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of linzagolix costs, country by country.
Normalised to the WHO defined daily dose (0.13 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Linzagolix · price per daily dose (0.13 g)
USD · FX 28 Sept 2026
- IT Italy$6.85
- ES Spain$5.81
The record
At a glance
URPL (Poland)- Active substance
- Linzagolixum cholini
- Manufacturer
- Theramex Ireland Limited
- Country
- Poland (PL)
- ATC code
- H01CC04
- ATC class
- Linzagolix
- Defined daily dose
- 0.13 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05060632509567
- gtin05060632509598
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under H01CC04
Linzagolix, as other registers publish it.
- IcelandYseltyTheramex Ireland Limited
- IcelandYseltyTheramex Ireland Limited
- DenmarkYseltyTheramex Ireland Limited
- PolandYseltyTheramex Ireland Limited
- DenmarkYseltyTheramex Ireland Limited
- FinlandYseltyTheramex Ireland Limited
- FinlandYseltyTheramex Ireland Limited
- CzechiaYSELTYTheramex Ireland Limited, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/333550a8-edc1-44e4-b49f-8e7e4f6e680b GET /v1/drugs/333550a8-edc1-44e4-b49f-8e7e4f6e680b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "100 mg",
"packaging": "05060632509567 ¦ Rpz ¦ EU/1/21/1606/001 ¦ 145696\n28 tabl.\n05060632509598 ¦ Rpz ¦ EU/1/21/1606/003 ¦ 152311\n84 tabl.",
"substance": "Linzagolixum cholini 100 mg",
"common_name": "Linzagolixum cholini",
"pl_product_id": "100470747",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about linzagolix.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.